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Abstract

Author Manuscript

Pulmonary complications are a significant cause for morbidity and mortality in osteogenesis
imperfecta (OI). However, to date, there have been few studies that have systematically evaluated
pulmonary function in individuals with OI. We analyzed spirometry measurements, including
forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1), in a large
cohort of individuals with OI (n=217) enrolled in a multicenter, observational study. We show that
individuals with the more severe form of the disease, OI type III, have significantly reduced FVC
and FEV1 which do not follow the expected trends of the normal population. We also show that
“normalization” of FVC and FEV1 using general population data to generate percent predicted
values underestimates the pulmonary involvement in OI. Within each subtype of OI, we used
linear mixed models to find potential correlations between FEV1 and FVC with the clinical
variables including mobility, bisphosphonate use, and scoliosis. Our results are an important step
in understanding the extent of pulmonary involvement in individuals with OI and for developing
pulmonary endpoints for use in the routine patient care as well as in the investigation of new
therapies.
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INTRODUCTION

Author Manuscript

Osteogenesis imperfecta (OI) refers to a phenotypically and genetically heterogeneous group
of Mendelian disorders that typically manifest with increased bone fragility, recurrent
fractures, bone deformities, short stature, hearing loss, and joint laxity1. OI can be caused by
pathogenic variants in genes that encode: 1) proα1(I) and proα2(I) chains of type I collagen,
2) proteins required for the posttranslational modification, processing, and crosslinking of
type I collagen, 3) components required for normal mineralization of bone, 4) transcription
and signaling proteins required for the maturation and function of osteoblasts, and 5) genes
whose functions are not completely understood to date1–4 More than 90% of OI occurs due
to qualitative or quantitative abnormalities of type I procollagen4,5. Individuals with type I
collagen- related OI are typically categorized by clinically severity into one of the four
Sillence types: nondeforming (type I), perinatally lethal (type II), progressively deforming
(type III), and common variable (type IV)2.
Type I collagen is widely expressed in the human body and is a component of the
extracellular matrix of many tissues and organs. Unsurprisingly, individuals with OI can also
manifest extraskeletal features that include pulmonary disease, muscle weakness, and
cardiovascular abnormalities6–10. Pulmonary disease is a significant contributor to the
mortality and morbidity in OI. In a register-based, nationwide cohort study from Denmark,
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Folkstead et al. reported that the subhazard ratio for deaths caused by respiratory diseases
was 3 times higher in OI as compared to the reference population11,12. The burden of
pulmonary disease in OI patients can be observed even during the neonatal period. Yimgang
et al. assessed the at-birth health outcomes of 77 neonates with OI (60 with OI type I, 4 with
OI type III, and 13 with OI type IV) and reported that 22% had respiratory complications in
the neonatal period13. These data demonstrate that pulmonary disease is a major contributor
to the morbidity and mortality in OI, especially in the more severe forms. To date, only 6
studies have systematically assessed pulmonary function using spirometry in individuals
with OI8–10,14–16. Most of these studies were limited by small sample size. The largest
study, to date, conducted by Wekre et al enrolled predominantly individuals with OI type I
and had only 3 individuals with OI type III.

Author Manuscript

Here, we investigated the pulmonary functions in 217 individuals with OI by the use of
spirometry. The participants were enrolled in a multicenter, observational, longitudinal study
conducted by the OI Linked Clinical Research Centers (LCRC). The study population
included children and adults with the mild, moderate, and severe forms of type I collagenrelated OI. We present the observed and predicted values for forced vital capacity (FVC) and
forced expiratory volume in the first second (FEV1) in each subtype of OI. We show that the
FVC and FEV1 in individuals with OI type III are significantly reduced and that the
“normalization” method to calculate the percent predicted values may underestimate the
pulmonary involvement in OI. Furthermore, we show potential correlations between FVC
and FEV1 with clinical covariates like mobility, bisphosphonate use, and scoliosis and
propose how these variables could be used to develop a OI-specific regression model to
assess spirometry in OI.

Author Manuscript

MATERIALS AND METHODS
Study Population

Author Manuscript

The establishment of the LCRC and subjects enrolled in the Longitudinal Study of
Osteogenesis Imperfecta have been previously described5,17. Participants were enrolled at
one of the five clinical sites: Baylor College of Medicine (Houston, TX); Kennedy Krieger
Institute (Baltimore, MD) and Nemours/Alfred I. DuPont Hospital for Children
(Wilmington, DE); Oregon Health & Science University and Shriners Hospital for Children
(Portland, OR); Shriners Hospital for Children (Chicago, IL); and Shriners Hospital for
Children (Montreal, QC). The Collagen Diagnostic Laboratory at the University of
Washington performed molecular and biochemical analyses. The study procedures were
approved by the Institutional Review Boards of all participating clinical sites and informed
consent was obtained from subjects or their legal guardians. The data collected from all of
the sites were managed by the NIH Rare Disease Clinical Research Network’s (RDCRN)
Data Management Coordinating Center at the College of Medicine, University of South
Florida (Tampa, FL).
Overall of the 558 participants enrolled in the longitudinal study, spirometry data were
available from 217 individuals (N=107 for OI type I, N=38 for OI type III, and N=55 for OI
type IV). Spirometry data were also available on small numbers of individuals with rarer
forms of OI, including OI type V (n=5), OI type VI (n=1), and OI type VII (n=2). The
Clin Genet. Author manuscript; available in PMC 2019 December 01.
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classification of type I collagen-related OI was made based on specific clinical
characteristics that were outlined in the manual of operations (Supplementary Table 1) and
whenever available, genotypic data were also used to determine the subtype of OI.
Data Collection

Author Manuscript

The following data were collected for analyses from the enrollment visit of the study: age,
gender, OI subtype, race and ethnicity, family history of OI (yes or no), height in cm, weight
in kg, arm span in cm, ambulatory status (wheelchair bound or not), and presence or absence
of scoliosis. These data were collected in a standardized manner across all sites according to
instructions outlined in the manual of operations and were reported using online case report
forms5. Height, defined as the vertical distance between crown of head and soles of feet, was
measured using a wall-mounted stadiometer and recorded to the nearest 0.1 cm. When
participants could not stand, supine length was measured from the heels to the top of the
head. Arm span was measured as the distance from one furthermost fingertip to the other
furthermost fingertip when the participant’s arms were stretched out horizontally using a
nonstretching long measuring tape to the nearest 0.1 cm. Arm span was measured in a single
measure and was not a composite of multiple measurements. Arm span was also used to
calculate height as previously described using the following formulae: 1) For Caucasian
males, height = arm span/1.03, 2) for African American men, height = arm span/1.06, and 3)
for women height = arm span/1.0118–20.

Author Manuscript
Author Manuscript

Spirometry was used to measure FVC and FEV1 in participants older than 6 years of age.
FVC is the maximal volume of air that can be exhaled with maximal effort from a position
of full inspiration and is typically reduced with airflow limitation or decreased lung capacity.
FEV1 is the maximal volume of air that can be exhaled in the first second of a forced
exhalation following a full inspiration and is the most important spirometric variable for
assessment of the severity of airflow obstruction. For spirometry, the equipment preparation,
calibration checks, participant preparation, and test administration were standardized across
all sites (Supplemental information S1). For each participant, spirometry test was repeated
until: three acceptable spirograms were obtained, a maximum of 8 tests had been performed,
or the participant could no longer continue in the single session. Spirograms were deemed
acceptable if they were free of artifacts, had good start volumes (volume <5% of FVC or
0.15 L, whichever was greater), and satisfactory exhalation (expiratory time duration of ≥6
seconds for individuals over 10 years of age OR ≥3 seconds for individuals under 10 years
of age, OR a plateau in the volume-time curve with evidence of a continuously forced
expiratory effort, where a plateau is defined as no change in volume for at least one second).
Individual spirometry test sessions were concluded if the two largest values of FVC were
within 0.15L of each other, and if the two largest values of FEV1 were within 0.15 L of each
other21,22.
Statistical Analysis
The Z-scores for height for children (age < 20 years) were calculated using growth data from
the Centers for Disease Control and Prevention (CDC)23. The height Z-scores for adults 20
years and older were calculated using the using the mean final adult height (SD) of 176.8 cm
(6.7 cm) and 163.3 cm (6.1 cm) for males and females, respectively from the CDC growth
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curves23. To visualize the trends in spirometry measures, the observed values for FVC and
FEV1 in L in OI types I, III and IV were plotted using scatter plots and non-parametric local
regression (LOESS) smoothing curves were added for each OI type. The predicted values of
FVC and FEV1 in L and FEV1/FVC ratio were calculated using reference population data
generated by Hankinson et al24 The predicted FVC and FEV1 values in individuals with OI
were compared with the predicted values for an age- and sex matched Caucasian population
obtained from the NHANES database24,25. Percent predicted values for FEV1 and FVC were
calculated by the formula (observed values/predicted value) × 100.

Author Manuscript

To elucidate the relationships between FVC and FEV1 with clinical covariates including age,
sex, stature, mobility, scoliosis, and treatment with bisphosphonates, we developed separate
linear models for OI types I, III, and IV using regression models (R)26. Hankinson et al.
have previously shown that in the general population, FVC and FEV1 correlate with age,
gender, height, age squared (age2), and height squared (height2). We developed a regression
model using these covariates and further refined the model by the addition of independent
variables specific to OI. This model included age, gender, height, age squared (age2), height
squared (height2), wheelchair bound (yes or no), scoliosis (yes or no), and history of
bisphosphonate use (yes or no) as well as interaction terms between gender and age, gender
and age2, and gender and height2. The model was refined by step-wise elimination of each
covariate until a combination of covariates reached the smallest AIC (Akaike Information
Criterion) value by applying stepAIC() function in MASS library in R.

RESULTS

Author Manuscript

The characteristics of individuals enrolled in the longitudinal study with spirometry data
available are outlined in Table 1. As would be expected, individuals with type I collagenrelated OI, the most common form of the disorder, accounted for 92% of all participants.
The number of individuals with the rarer forms of OI were limited (n=16) and thus, this
population was excluded from statistical analyses.
Observed FEV1 and FVC in OI

Author Manuscript

Across all ages, both males and females with OI type III had lower FVC and FEV1 than
those with OI types I and IV (Figure 1). The differences were most apparent between the
second and fourth decades of life. FVC and FEV1 were lower in females with OI type IV
than those with OI type I, but a similar difference was not observed in males. FVC and FEV1
increased during the first three decades of life and gradually decreased thereafter in
individuals with OI types I and IV. This is consistent with and comparable to the pattern in
the general population24. The age-related increases were significantly blunted in OI type III.
A FEV1 of less than 1.5 L is considered as a marker of moderate airway impairment in the
general adult population irrespective of the predicted value27,28. Whereas no adults with OI
type I and only two adults with OI type IV (9.5%) had FEV1 of less than 1.5 L, 65% (11 out
of 17) of adults with OI type III had FEV1 less than 1.5 L (χ2 test, p<0.0001). As FEV1 and
FVC were both decreased proportionately, the FEV1/FVC ratios were similar between all
three subtypes of collagen I-related OI (Supplementary Figure 1).
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It is an accepted standard practice to “normalize” the observed FEV1 and FVC based on
predictions for gender, race, age, and height of an individual21,22,25. We calculated the
predicted FEV1 and FVC values based on regression for gender, race, age, and height from
the general population data and subsequently calculated a percent predicted value for FVC
and FEV1 in OI.24 Calculation of predicted volumes allowed for comparison of FVC and
FEV1 in each OI type with the general population. As expected because of decreased height,
the predicted FEV1 and FVC were lower in individuals with OI types III and IV compared to
the general population and individuals with OI type l (Figure 2). The deviation from the
predicted general population values was least for those with OI type I males. This is likely
because predicted values correlate with height. The mean height Z-scores for OI type I was
−1.2, whereas the Z-scores for OI types III and IV were −8.3 and −3.5, respectively
(Supplementary Figure 2). Even though individuals with OI type III had lower observed
FVC and FEV1, the “normalization” resulted in percent predicted values being no different
from OI types I and IV (Supplementary figure 3).
As the accurate measurement of height in type III and IV OI can be difficult due to bowing
of lower limb bones, scoliosis, and inability to stand, we also calculated the height based on
arm span18–20. The coefficient of correlations between the measured height and arm span
calculated height were 0.89, 0.54, and 0.67 for OI types I, III, and IV, respectively; which
suggested that measured height more closely correlated with arm span calculated height in
milder forms of OI (Supplementary Figure 4). The predicted FEV1 and FVC were
comparable when using either measured height or arm span calculated height in OI types I
and IV, the predicted volumes changed significantly with the use of use of arm span imputed
height in OI type III (Supplementary Figure 5).

Author Manuscript
Author Manuscript

Development of an OI-specific regression model for predicting FEV1 and FVC
—One limitation of implementing the regression parameters developed by Hankinson et al.
in individuals with OI is that the distribution of height in OI is different from the general
population height. Additionally, the model does not account for limited mobility, scoliosis,
and abnormal shape of the chest in OI. We attempted to develop linear models to refine
calculating the predicted FEV1 and FVC in each subtype of type I collagen-related OI. A
step-wise backward selection approach was used to select the covariates. The naïve model
included age, height, gender, age2, height2, gender*age, gender*age2, gender*height2,
mobility (wheel-chair bound or ambulatory), self-reported scoliosis (yes or no), history of
bisphosphonate use (yes or no). As the vast majority of individuals in our cohort were white,
race was omitted in the naïve model. After stepwise selection, the final models were
generated and presented separately for males and females accounting for the interaction
terms (Table 2).
In OI type I, where 97% of individuals were ambulatory and only 27% reported scoliosis, we
found that age, age2, and height2, correlated significantly with the observed FEV1 and FVC.
This is similar to the regression results in the general population reported by Hankinson. In
individuals with OI type III, not wheelchair bound was associated significantly with a higher
FEV1 in both males and females, whereas presence of scoliosis showed a negative
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correlation with FVC. In OI type IV, a significant association between bisphosphonate use
and FEV1 was observed.

DISCUSSION

Author Manuscript

To date, only 6 studies have systematically assessed pulmonary functions in OI8–10,14–16. In
most of these studies, spirometry has been used as a primary measure of pulmonary function
(Table 3). In one of these studies, LoMauro and colleagues performed a comprehensive
analysis of lung functions in OI using standard spirometry, nocturnal oxygen saturation,
radiographs, opto-electronic plethysmography and kinematic analysis and showed that in
addition to abnormal spirometry volumes, individuals with OI type III had paradoxical
inspiratory inward motion of the pulmonary rib cage and thoraco-abdominal asynchronies15.
However, it is not possible to perform such sophisticated analyses in the clinical settings and
most physicians use spirometry as the main measure of pulmonary function in routine
patient care.

Author Manuscript

In the current study, we measured FVC and FEV1 in 217 individuals with OI. The strengths
of our study are the following: 1) to, date, this is the largest study to evaluate spirometry
measures in OI, 2) the study population included both children and adults with varying
degrees of severity, 3) the data were collected in a systematic manner from sites with
extensive experience in the management of OI, 4) the sample size and other phenotypic
characteristics allowed for robust statistical evaluations, and 5) patients were enrolled from
across North America and thus our findings are more likely to be representative of the
spirometry values from the OI population at large. We show that across all ranges, the FVC
and FEV1 are significantly lower in individuals with OI type III when compared to
individuals in the general population and those with OI types I and IV. Whereas the pattern
of increase in FVC and FEV1 with age in individuals with OI types I and IV are consistent
with the general population data albeit with lower volumes, there is significant blunting of
the age-related increases in OI type III and two-thirds of adults with OI type III have FEV1
of less than 1.5 L.

Author Manuscript

A key question to be answered is whether these diminished volumes are “appropriate-forsize” in OI or whether they portend poor cardiopulmonary outcomes. In the NHANES I
cohort, 4300 men and women (age range 25–74 years) were followed for an average of 13
years; a 1-liter decrement in FEV1 in the cohort, was associated with a 60% increase in
mortality even when accounting for sex, race, age, serum cholesterol, systolic blood
pressure, smoking status, alcohol consumption, and body mass index29,30. Similarly, in the
Normative Aging Study of 1,956 men (age range 21–80 years) who were followed for 30
years, a 1-liter decrement in FEV1 at enrollment was associated with a relative risk of 1.67
for all-cause mortality (RR = 1.67, 95 percent CI 1.25–2.22) after adjusting for age, white
cell count, serum cholesterol, systolic blood pressure, and smoking status31. In individuals
with chronic obstructive lung disease (who by definition have decreased FEV1), lower FVC
and FEV1 have not only been associated with increased overall mortality, but also outcomes
during recovery from stressful situations such as acute exacerbations or cardiac surgery32,33.
Whereas, the ability to predict the implications of low FVC and FEV1 in OI based on data
from the general population and individuals with chronic obstructive pulmonary disease has
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significant limitations, it is possible that low pulmonary volumes in OI type III may interfere
with the ability to respond to stressful situations like concomitant airway disease, pulmonary
infections, and surgery.

Author Manuscript

In the general population, FVC and FEV1 are used to categorize the lung diseases into
“restrictive” and “obstructive” categories. Restrictive lung physiology is characterized by
symmetrically reduced lung volumes, typically defined by reduced FVC and FEV1 and thus
a normal or increased FEV1/FVC ratio. Obstructive lung physiology characterized by
resistance to expiratory airflow is defined by a FEV1/FVC ratio less than 0.7 (which is the
lower limit of normal) and an FEV1 of less than 80 percent of predicted. A major limitation
in the use of spirometric measures in OI is that the observed values have to be normalized
based on age and stature of an individual. FVC and FEV1 measurements are typically
compared to predicted values based on age, height, gender and ethnicity generated from the
general population. We show that while this normalization process is appropriate for
individuals with OI type I, it can lead to underestimation of the diminished FVC and FEV1
in individuals with OI type III. Thus, categorizing individuals with OI into “obstructive” and
“restrictive” categories using the standard definitions is likely to be complicated. Using
phenotypic data from the cohort, we tried to develop a regression model that uses age and
height and incorporates mobility, scoliosis, and history of bisphosphonate use to predict
FEV1 and FVC in OI types III and IV. These preliminary analyses showed that these
covariates could be used to generate an OI-specific regression model.

Author Manuscript

There are limitations of the data set and the analyses that we have been able to perform.
First, we have only conducted analyses on FVC and FEV1 from the enrollment visit. As only
few individuals had repeated spirometric measures, we could not assess changes over time.
Second, only FVC and FEV1 were systematically collected by electronic case report forms;
maximal mid-expiratory flow rate (FEF25–75), forced expiratory volume in six seconds
(FEV6), residual volume, total lung capacity, and diffusing capacity for carbon monoxide
were not available. Third, treatment with bisphosphonates was used as a binary variable on
an individual level; the dates of BPN treatment were not collected and thus analysis on the
effects of long-term vs short-term treatment, remote vs concurrent treatment could not be
performed. Fourth, scoliosis data was obtained by various methods including radiography,
medical records, and self-reporting. The degree of scoliosis was not assessed systematically,
and we could not correlate between varying degrees of scoliosis and lung functions. Fifth,
due to clustering of the mobility data, effect of mobility could only be assessed using a
dichotomous variable of whether individuals were mobile, or wheelchair bound.

Author Manuscript

Pulmonary disease in OI is multifactorial and can be a result of factors extrinsic to the lungs,
as well as intrinsic lung abnormalities. Whereas the relevance of extrinsic factors, including
short stature, immobility, scoliosis, recurrent rib fractures, muscle weakness, and chest wall
abnormalities on pulmonary disease have been well documented10,14,15, the extent of
intrinsic pulmonary abnormalities and the additional mechanisms that cause lung
abnormalities in OI have been discovered recently using animal models of OI16,34–36. Thiele
and colleagues studied Aga2/+ mice, a murine model of OI in which a single nucleotide
change in the last intron introduces a new splice acceptor site which introduces a frame shift
and extends the transcript beyond the usual stop site16,37. Mutations in humans that have the

Clin Genet. Author manuscript; available in PMC 2019 December 01.

Tam et al.

Page 9

Author Manuscript
Author Manuscript

same effect of extending the transcript lead to stable mRNA but very unstable protein and an
OI type I phenotype with marked intrafamilial variability38. In the Aga2/+ mice, Thiele and
colleagues found diffuse pulmonary hemorrhage and inflammation that appeared to be
independent of fracture16. Primary lung fibroblasts showed an altered gene expression
profile consistent with altered markers of inflammation, hypoxia, and a generalized
dysregulation of extracellular matrix. The subset of severely affected mice (Aga2severe) had
decreased partial pressure of oxygen and increased partial pressure of carbon dioxide
suggesting respiratory failure. It is to be noted that the Aga2severe mice also demonstrated
right ventricular hypertrophy, abnormal cardiac collagen matrix, and decreased fractional
shortening. abnormalities. In a different mouse model of severe form of type I collagenrelated OI which harbors a splice site mutation in intron 9, Col1a1 (Col1a1Jrt/+), that results
in skipping exon 9, Baglole and colleagues demonstrated alveolar airspace enlargement and
that the number of fibers, thickness, and contractility of the diaphragm were reduced35. In a
recessive murine model of OI (Crtap−/−) that recapitulates human OI type VIII, Baldridge
and colleagues showed alveolar air space enlargement34,39. Subsequently, Grafe et al.
showed that excessive transforming growth factor-β (TGF-β) signaling is a contributing
mechanism for the pulmonary phenotype in Crtap−/− mice and that anti-TGFβ treatment, at
least in part, rescues the phenotype of increased air space enlargement36. Whereas there are
limited data regarding histological pulmonary abnormalities in humans with OI, decreased
alveolar number and immature acinar development (similar to changes in the murine
models), and pulmonary hypoplasia have reported in autopsies in the perinatal lethal form of
OI40–43.

Author Manuscript
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The findings in this study have implications for clinical care and identify areas where further
research is needed. We recommend that clinicians assess pulmonary function in individuals
with OI as part of the routine first evaluation. Spirometry should be considered in all
individuals with OI, especially in those with OI types III and IV. Referral to a pulmonologist
should be made based on symptomatology and spirometry results. While interpreting
spirometry results, clinicians need to be aware of the limitations of calculating predicted and
percent predicted values in OI. In individuals with no significant bone deformities or
scoliosis, the predicted values may be calculated using measured height. In individuals with
significant lower extremity bone deformities and scoliosis who do not have upper extremity
long bone abnormalities, arm span calculated height may be more appropriate to calculate
predicted values. In individuals with severe OI, who have multiple bone deformities, using
either measured height or arm span calculated height is likely to underestimate the
pulmonary involvement and, in such individuals, serial monitoring of observed FCV and
FEV1 is probably the most reasonable way to assess pulmonary functions. In individuals
who have low FEV1 or FVC, we recommend that periodic spirometry tests be done. In
individuals with decreased pulmonary reserve, like adults with FEV1 less than 1.5 L,
pneumococcal vaccination and annual influenza vaccination should be considered.
Clinicians should also be aware that the dynamic stress on ribs caused during spirometry can
increase the risk for rib fractures in individuals with severe forms of OI and appropriate
precautions should be taken during performance of the test.
On the research front, we believe that this study is an important first step in developing OIspecific standards to predict FVC and FEV1 and in developing pulmonary endpoints for
Clin Genet. Author manuscript; available in PMC 2019 December 01.
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clinical research. Whereas FVC and FEV1 measurement remain the mainstays of evaluation
of pulmonary physiology, more sophisticated measures may provide additional information.
In assessing the contribution of abnormal chest wall architecture versus intrinsic lung
abnormalities, the most direct, but somewhat invasive, method would be to measure
intrapleural pressure using an esophageal balloon. Kyphoscoliosis, rib and vertebral
fractures would lead to the generation of low negative intrapleural pressures during
inhalation while restrictive lung disease due to connective tissue abnormalities would lead to
the generation of very high negative intrapleural. Plethysmographic lung volumes,
assessment of air flow and peak inspiratory and expiratory pressures, and the measurement
of diffusing capacity and gas transfer will add to our understanding of the characteristics of
the pulmonary physiology and risks in OI. Impulse oscillometry, a noninvasive, rapid, safe
and validated technique that measures respiratory impedance is another modality that
requires further study in OI.

Author Manuscript

In conclusion, we show that the normalization process used in spirometry analyses can
underestimate the pulmonary involvement in severe forms of OI. We suggest that clinicians
be aware of the limitations of spirometric measures when evaluating pulmonary function in
OI.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1:

Author Manuscript

Observed FVC and FEV1 in type I collagen-related OI. Each dot represents observed FVC
and FEV1 from the baseline visit of a single participant. The Lines represent the LOESS
regression lines for each OI type. Whereas OI types I and IV demonstrate age-related
increase in FVC and FEV1, such changes are absent in OI type III.
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Figure 2:
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Predicted FVC and FEV1 values were calculated using reference population data generated
by Hankinson et al. Each dot represents predicted FVC and FEV1 for a single participant.
The lines represent the LOESS regression lines for control population and each OI type.
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Author Manuscript

Characteristics of individuals with OI enrolled in the study

Author Manuscript

OI I

OI III

OI IV

Others

104

37

52

16

Male n (%)

49 (47.1)

13 (35.1)

18 (34.6)

6 (37.5)

Female n (%)

55 (52.8)

24 (64.8)

34 (65.3)

10 (62.5)

27.2 (6.1–67.2)

23.9 (7.8–53.9)

25.0 (6.8–62.7)

17.1 (6.2–48.0)

White

104 (100)

34 (91.9)

45 (86.5)

12 (75)

Black

0 (0)

3 (8.1)

7 (13.5)

2 (12.5)

Scoliosis n (%)

28 (26.9)

29 (78.4)

22 (42.3)

10 (62.5)

Wheelchair bound n (%)

3 (2.9)

19 (51.4)

9 (17.3)

9 (56.2)

History of bisphosphonate use n (%)

49 (47.1)

30 (81.1)

34 (65.4)

10 (62.5)

Total number n

Mean age in years (range)
Race n (%)
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Table 2:
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Linear model to refine the predicted FVC and FEV1 in OI
Intercept

Age (year) β1

Age2 (year2) β2

Height2 (cm) β3

Mobility β4

Scoliosis β5

Bisphosphonate β6

Female subjects
OI type
I

FEV1

0.06841

0.08875

−0.00128

0.00005

I

FVC

−0.28034

0.11847

−0.00165

0.00007

III

FEV1

−0.93779

0.05093

−0.00128

0.00014

III

FVC

−1.39049

0.10352

−0.00214

0.00017

IV

FEV1

0.28869

0.04383

−0.00066

0.00007

IV

FVC

−0.08906

0.07294

−0.00107

0.00009

0.31692
−0.33132
−0.20545

Male subjects

Author Manuscript

OI type
I

FEV1

−0.971

0.2153

−0.00336

0.00005

I

FVC

−0.97289

0.11847

−0.00165

0.00012

III

FEV1

−0.82984

0.05093

−0.00077

0.00014

III

FVC

−1.31875

0.10352

−0.00133

0.00017

IV

FEV1

−0.82372

0.16285

−0.00218

0.00007

IV

FVC

−1.10702

0.18679

−0.00251

0.00009

0.31692
−0.33132
−0.20545

The linear model to evaluate correlation between FVC or FEV1 and other clinical covariates. FVC and FEV1 were calculated using the equation
Intercept + β1 ∗ Age + β2 ∗ Age2 + β3 ∗ Height2 + β4 ∗ Mobility + β5 ∗ Scoliosis + β6 ∗ Bisphosphonate. The values in the table represent β
coefficients. Cells without any numbers imply that the covariates were excluded in the stepwise selection used to refine the linear model. For age
and height, nominal data were used. For mobility, wheel chair bound was represented as 0 and not wheel chair bound was represented as 1. For
scoliosis, 0 represented no scoliosis and 1 represented presence of scoliosis. Similarly, history of ever exposure to bisphosphonates was represented

Author Manuscript

as 0 and 1 represents history of treatment with BPN. R2 values for the model predicting variability in FVC and FEV1 across OI types were 0.70–
0.79 and 0.63–0.72, respectively.
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Table 3:

Author Manuscript

Studies that have evaluated pulmonary functions in Ol
Study

Number enrolled

Age

Falvo et al 1973

“severe disease” 4
“moderate disease” 6
“mild disease” 1

4–34 yrs

Widmann et al
1999

“OI tarda” 8
“OI congenita” 7

21–45 yrs

Takken et al
2004

OI I 17

8–21 yrs

Thiele et al 2012

OI III 23
OI IV 23

4–20 yrs

Major Findings
•

Reduction of VC and increase in RV and RV/TLC ratio were
found only in patients with kyphoscoliosis

Author Manuscript

•

“Restrictive disease” in 53%

•

Diminished VC with scoliosis of greater than 600

•

Decrease in percent predicted FEV1 and FVC with
normalized height but not measured height

•

Decreased exercise tolerance

•

FVC, VC, and TLC decrease with age

•

Decline in volumes is greater in type III OI

•

Scoliosis contributes to decline in volumes; however decline
observed even in absence of scoliosis

•

57% diagnosed with “restrictive disease”

•

22% diagnosed with “obstructive disease”

LoMauro et al
2012

OI III 7
OI IV 15

Mean (SD) OI III
26 (16) yrs
Mean (SD) OI
IV 16 (11) yrs

•

Lower FVC and FEV1 compared to predicted values

•

Paradoxical movement of chest wall and thoracoabdominal
asynchrony in type III OI

Wekre et al 2014

OI I 60
OI III 3
OI IV 10

Mean (SD)
44 (12)

•

Use of arm span-imputed height decreased percent predicted
FVC and FEV1 compared to measure height

•

FVC and FEV1 correlated negatively with scoliosis
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